Inicio・Lista de Acciones・Novavax Inc

Novavax Inc

Cerrado

SectorSanidad

8.08 2.02

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.85

Máximo

8.12

Métricas clave
By Trading Economics
Ingresos	-27M -9.5M
Ventas	-7.6M 140M
P/B Media del Sector	3.112 60.149
BPA	-0.06
Margen de beneficios	-6.803
Empleados	749
EBITDA	-29M -543K

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+36.42% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	214M 1.5B
Apertura anterior	6.06
Cierre anterior	8.08

Noticias sobre sentimiento de mercado

By Acuity

32%

68%

81 / 340 Clasificación en Healthcare

Novavax Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 jul 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Comparación entre iguales

Cambio de precio

Novavax Inc previsión

Precio Objetivo

By TipRanks

36.42% repunte

Estimación a 12 Meses

Media 10.75 USD 36.42%

Máximo 19 USD

Mínimo 7 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novavax Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Novavax Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

81 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.